Selected research
Industry Research
Buclizine Industry Research Report 2026
Market perspective
The global Buclizine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Buclizine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Buclizine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Buclizine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Buclizine include Sanofi, Johnson and Johnson, Pfizer, UCB, Stuart Pharmaceuticals, Sinphar, Peili Pharmaceutical, MK Pharma and Meider Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Buclizine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Buclizine Market by Company
Sanofi
Johnson and Johnson
Pfizer
UCB
Stuart Pharmaceuticals
Sinphar
Peili Pharmaceutical
MK Pharma
Meider Pharma
Mankind Pharma
Laboratorios Rocnarf
HUA Shin Chemical Pharmaceutical
Al Pharm
Buclizine Segment by Type
Hospital
Drug Store
Buclizine Segment by Application
Antiallergic Agent
Histamine H₁-Receptor Antagonist
Buclizine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Buclizine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Buclizine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Buclizine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Buclizine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Buclizine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Buclizine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hospital
- Drug Store
Applications
- Antiallergic Agent
- Histamine H₁-Receptor Antagonist
Companies covered
- Sanofi
- Johnson and Johnson
- Pfizer
- UCB
- Stuart Pharmaceuticals
- Sinphar
- Peili Pharmaceutical
- MK Pharma
- Meider Pharma
- Mankind Pharma
- Laboratorios Rocnarf
- HUA Shin Chemical Pharmaceutical
- Al Pharm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Buclizine Market Size (2021-2032)
- 2.2.2 Global Buclizine Sales (2021-2032)
- 2.2.3 Global Buclizine Market Average Price (2021-2032)
- 2.3 Buclizine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hospital
- 2.3.3 Drug Store
- 2.4 Buclizine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Antiallergic Agent
- 2.4.3 Histamine H₁-Receptor Antagonist
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Buclizine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Buclizine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Buclizine Revenue of Manufacturers (2021-2026)
- 3.4 Global Buclizine Average Price by Manufacturers (2021-2026)
- 3.5 Global Buclizine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Buclizine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Buclizine, Product Type & Application
- 3.8 Global Manufacturers of Buclizine, Established Date
- 3.9 Global Buclizine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Buclizine Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Johnson and Johnson
- 4.2.1 Johnson and Johnson Company Information
- 4.2.2 Johnson and Johnson Business Overview
- 4.2.3 Johnson and Johnson Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson and Johnson Buclizine Product Portfolio
- 4.2.5 Johnson and Johnson Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Buclizine Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 UCB
- 4.4.1 UCB Company Information
- 4.4.2 UCB Business Overview
- 4.4.3 UCB Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 UCB Buclizine Product Portfolio
- 4.4.5 UCB Recent Developments
- 4.5 Stuart Pharmaceuticals
- 4.5.1 Stuart Pharmaceuticals Company Information
- 4.5.2 Stuart Pharmaceuticals Business Overview
- 4.5.3 Stuart Pharmaceuticals Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Stuart Pharmaceuticals Buclizine Product Portfolio
- 4.5.5 Stuart Pharmaceuticals Recent Developments
- 4.6 Sinphar
- 4.6.1 Sinphar Company Information
- 4.6.2 Sinphar Business Overview
- 4.6.3 Sinphar Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sinphar Buclizine Product Portfolio
- 4.6.5 Sinphar Recent Developments
- 4.7 Peili Pharmaceutical
- 4.7.1 Peili Pharmaceutical Company Information
- 4.7.2 Peili Pharmaceutical Business Overview
- 4.7.3 Peili Pharmaceutical Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Peili Pharmaceutical Buclizine Product Portfolio
- 4.7.5 Peili Pharmaceutical Recent Developments
- 4.8 MK Pharma
- 4.8.1 MK Pharma Company Information
- 4.8.2 MK Pharma Business Overview
- 4.8.3 MK Pharma Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 MK Pharma Buclizine Product Portfolio
- 4.8.5 MK Pharma Recent Developments
- 4.9 Meider Pharma
- 4.9.1 Meider Pharma Company Information
- 4.9.2 Meider Pharma Business Overview
- 4.9.3 Meider Pharma Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Meider Pharma Buclizine Product Portfolio
- 4.9.5 Meider Pharma Recent Developments
- 4.10 Mankind Pharma
- 4.10.1 Mankind Pharma Company Information
- 4.10.2 Mankind Pharma Business Overview
- 4.10.3 Mankind Pharma Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mankind Pharma Buclizine Product Portfolio
- 4.10.5 Mankind Pharma Recent Developments
- 4.11 Laboratorios Rocnarf
- 4.11.1 Laboratorios Rocnarf Company Information
- 4.11.2 Laboratorios Rocnarf Business Overview
- 4.11.3 Laboratorios Rocnarf Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Laboratorios Rocnarf Buclizine Product Portfolio
- 4.11.5 Laboratorios Rocnarf Recent Developments
- 4.12 HUA Shin Chemical Pharmaceutical
- 4.12.1 HUA Shin Chemical Pharmaceutical Company Information
- 4.12.2 HUA Shin Chemical Pharmaceutical Business Overview
- 4.12.3 HUA Shin Chemical Pharmaceutical Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 HUA Shin Chemical Pharmaceutical Buclizine Product Portfolio
- 4.12.5 HUA Shin Chemical Pharmaceutical Recent Developments
- 4.13 Al Pharm
- 4.13.1 Al Pharm Company Information
- 4.13.2 Al Pharm Business Overview
- 4.13.3 Al Pharm Buclizine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Al Pharm Buclizine Product Portfolio
- 4.13.5 Al Pharm Recent Developments
5 Global Buclizine Market Scenario by Region
- 5.1 Global Buclizine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Buclizine Sales by Region: 2021-2032
- 5.2.1 Global Buclizine Sales by Region: 2021-2026
- 5.2.2 Global Buclizine Sales by Region: 2027-2032
- 5.3 Global Buclizine Revenue by Region: 2021-2032
- 5.3.1 Global Buclizine Revenue by Region: 2021-2026
- 5.3.2 Global Buclizine Revenue by Region: 2027-2032
- 5.4 North America Buclizine Market Facts & Figures by Country
- 5.4.1 North America Buclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Buclizine Sales by Country (2021-2032)
- 5.4.3 North America Buclizine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Buclizine Market Facts & Figures by Country
- 5.5.1 Europe Buclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Buclizine Sales by Country (2021-2032)
- 5.5.3 Europe Buclizine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Buclizine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Buclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Buclizine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Buclizine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Buclizine Market Facts & Figures by Country
- 5.7.1 South America Buclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Buclizine Sales by Country (2021-2032)
- 5.7.3 South America Buclizine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Buclizine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Buclizine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Buclizine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Buclizine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Buclizine Sales by Type (2021-2032)
- 6.1.1 Global Buclizine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Buclizine Sales Market Share by Type (2021-2032)
- 6.2 Global Buclizine Revenue by Type (2021-2032)
- 6.2.1 Global Buclizine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Buclizine Revenue Market Share by Type (2021-2032)
- 6.3 Global Buclizine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Buclizine Sales by Application (2021-2032)
- 7.1.1 Global Buclizine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Buclizine Sales Market Share by Application (2021-2032)
- 7.2 Global Buclizine Revenue by Application (2021-2032)
- 7.2.1 Global Buclizine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Buclizine Revenue Market Share by Application (2021-2032)
- 7.3 Global Buclizine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Buclizine Value Chain Analysis
- 8.1.1 Buclizine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Buclizine Production Mode & Process
- 8.2 Buclizine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Buclizine Distributors
- 8.2.3 Buclizine Customers
9 Global Buclizine Analyzing Market Dynamics
- 9.1 Buclizine Industry Trends
- 9.2 Buclizine Industry Drivers
- 9.3 Buclizine Industry Opportunities and Challenges
- 9.4 Buclizine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst